Abeona Therapeutics Q1 net loss $9.1M; cash runway into Q3 2024; advancing EB-101 BLA submission

ABEONA THERAPEUTICS INC.

2024-Q1 EPS reported -$0.54

Net loss of $9.1M ($0.54 loss per share) vs $22.0M ($3.80) in Q1 2022; license revenue nil.
Cash, equivalents, short-term investments $40.7M at Mar 31, 2023, down from $52.5M at Dec 31, 2022; cash runway into Q3 2024.
Progress toward BLA submission for EB-101 in RDEB in late Q2/early Q3 2023; pre-BLA meeting request submitted to FDA.
Additional Phase 3 VIITAL data presented at ISID; preclinical AAV ophthalmology data (ABO-504, ABO-503, ABO-505) at ASGCT May 16-20.
R&D expenses $8.0M, G&A $4.0M for Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

ABEONA THERAPEUTICS INC. reported the first quarter of 2023 results: revenue nil, net income Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share, EPS $0.54 loss per common share. Guidance reaffirmed.

Period: the first quarter of 2023
Revenue: nil
Net income: Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share
EPS: $0.54 loss per common share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Abeona Therapeutics Inc. issued a press release regarding its results of operations and financial condition for the first quarter of 2023.

View on SEC.gov

Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-016277

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.